BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abufaraj M, Dalbagni G, Daneshmand S, Horenblas S, Kamat AM, Kanzaki R, Zlotta AR, Shariat SF. The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. Eur Urol 2018;73:543-57. [PMID: 29122377 DOI: 10.1016/j.eururo.2017.09.030] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
Number Citing Articles
1 Xiong M, Chen L, Zhou L, Ding Y, Kazobinka G, Chen Z, Hou T. NUDT21 inhibits bladder cancer progression through ANXA2 and LIMK2 by alternative polyadenylation. Theranostics 2019;9:7156-67. [PMID: 31695759 DOI: 10.7150/thno.36030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
2 Wang R, Zheng Z, Mao S, Zhang W, Liu J, Li C, Liu S, Yao X. Construction and Validation of a Novel Eight-Gene Risk Signature to Predict the Progression and Prognosis of Bladder Cancer. Front Oncol 2021;11:632459. [PMID: 34268106 DOI: 10.3389/fonc.2021.632459] [Reference Citation Analysis]
3 Chen S, Jiang L, Zhang E, Hu S, Wang T, Gao F, Zhang N, Wang X, Zheng J. A Novel Nomogram Based on Machine Learning-Pathomics Signature and Neutrophil to Lymphocyte Ratio for Survival Prediction of Bladder Cancer Patients. Front Oncol 2021;11:703033. [PMID: 34222026 DOI: 10.3389/fonc.2021.703033] [Reference Citation Analysis]
4 Chen S, Zhang N, Shao J, Wang T, Wang X. A novel gene signature combination improves the prediction of overall survival in urinary bladder cancer. J Cancer 2019;10:5744-53. [PMID: 31737111 DOI: 10.7150/jca.30307] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
5 Packiam VT. Consensus statements from the EAU-ESMO collaboration for advanced and variant bladder cancer: can we move the needle to improve survival? Transl Androl Urol 2020;9:2488-92. [PMID: 33457222 DOI: 10.21037/tau-20-934] [Reference Citation Analysis]
6 Aydh A, Abufaraj M, Mori K, Quhal F, Pradere B, Motlagh RS, Mostafaei H, Karakiewicz PI, Shariat SF. Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review. Arab J Urol 2020;19:59-66. [PMID: 33763249 DOI: 10.1080/2090598X.2020.1858012] [Reference Citation Analysis]
7 Lim AH, Narayan VM, Navai N. The Role of Surgery in Initially Metastatic Urothelial Carcinoma: Informing a Definitive Trial. Eur Urol Oncol 2020;3:102-3. [PMID: 31501083 DOI: 10.1016/j.euo.2019.08.006] [Reference Citation Analysis]
8 Kobayashi M, Tanaka H, Tateishi U, Numao N, Yonese J, Ito M, Koga F, Fukushima H, Uehara S, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y. Impact of fluorodeoxyglucose uptake on positron emission tomography/computed tomography on chemosensitivity and survival in patients with metastatic urothelial carcinoma. Int J Urol 2019;26:820-6. [PMID: 31140215 DOI: 10.1111/iju.14022] [Reference Citation Analysis]
9 Moussa M, Chakra MA, Papatsoris A, Dellis A, Saad W, Chahine NB. Inguinal lymph node metastasis of bladder carcinoma after radical cystectomy: A case report and review of literature. Int J Surg Case Rep 2020;75:385-9. [PMID: 32992094 DOI: 10.1016/j.ijscr.2020.09.068] [Reference Citation Analysis]
10 Staník M, Poprach A, Zapletalová M, Krejčí D, Macík D, Čapák I, Jarkovský J, Lakomý R, Doležel J. Comparison of Different Treatment Modalities Outcomes in Clinically Node-positive Bladder Cancer: Analysis of a Population-based Cancer Registry. Clinical Genitourinary Cancer 2019;17:e759-67. [DOI: 10.1016/j.clgc.2019.04.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
11 Paciotti M, Nguyen DD, Modonutti D, Haeuser L, Lipsitz S, Mossanen M, Kibel AS, Lughezzani G, Trinh QD, Cole AP. Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. Urol Oncol 2021;39:436.e1-436.e10. [PMID: 33736978 DOI: 10.1016/j.urolonc.2021.01.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 König F, Shariat SF, Karakiewicz PI, Mun DH, Rink M, Pradere B. Quality indicators for the management of high-risk upper tract urothelial carcinoma requiring radical nephroureterectomy. Curr Opin Urol 2021;31:291-6. [PMID: 33973537 DOI: 10.1097/MOU.0000000000000895] [Reference Citation Analysis]
13 Luo H, Yang L, Liu C, Wang X, Dong Q, Liu L, Wei Q. TMPO-AS1/miR-98-5p/EBF1 feedback loop contributes to the progression of bladder cancer. Int J Biochem Cell Biol 2020;122:105702. [PMID: 32087328 DOI: 10.1016/j.biocel.2020.105702] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
14 Kim H, Lee SJ, Lee IK, Min SC, Sung HH, Jeong BC, Lee J, Park SH. Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells. Int J Mol Sci 2020;21:E2825. [PMID: 32325639 DOI: 10.3390/ijms21082825] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
15 Shi X, Huang NS, Shi RL, Wei WJ, Wang YL, Ji QH. Prognostic value of primary tumor surgery in minor salivary-gland carcinoma patients with distant metastases at diagnosis: first evidence from a SEER-based study. Cancer Manag Res 2018;10:2163-72. [PMID: 30050326 DOI: 10.2147/CMAR.S172725] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
16 Guo Y, Jie X, Zhang A, Zhang W, Wang R, Zhang J, Mao S, Wu Y, Wang L, Zhang Z, Yan Y, Wang P, Yao X. Evaluation of Survival Outcomes With Trimodal Therapy as Primary Therapy for Non-organ-confined Bladder Cancer. Front Oncol 2019;9:1315. [PMID: 31867271 DOI: 10.3389/fonc.2019.01315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Yahya EB, Alqadhi AM. Recent trends in cancer therapy: A review on the current state of gene delivery. Life Sci 2021;269:119087. [PMID: 33476633 DOI: 10.1016/j.lfs.2021.119087] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
18 Gao Q, Liu Y, Xie H, Zhong Y, Liao X, Zhan H, Zhou Q, Ding M, Yang K, Li A, Liu Y, Mei H, Cai Z. Lentivirus-mediated shRNA targeting MUTYH inhibits malignant phenotypes of bladder cancer SW780 cells. Onco Targets Ther 2018;11:6101-9. [PMID: 30275714 DOI: 10.2147/OTT.S174223] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Abufaraj M, Al-Ani A, AlQudah A, Shariat SF. Surgical intervention in patients with urothelial carcinoma of the bladder and lymph node metastasis. Curr Opin Urol 2021;31:220-5. [PMID: 33742983 DOI: 10.1097/MOU.0000000000000866] [Reference Citation Analysis]
20 Warren M, Kolinsky M, Canil CM, Czaykowski P, Sridhar SS, Black PC, Booth CM, Kassouf W, Eapen L, Mukherjee SD, Blais N, Eigl BJ, Winquist E, Basappa NS, North SA; GUMOC. Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. Can Urol Assoc J 2019;:318-27. [PMID: 31059420 DOI: 10.5489/cuaj.6015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
21 Lai C, Wu Z, Shi J, Li K, Zhu J, Chen Z, Liu C, Xu K. Autophagy-related long noncoding RNAs can predict prognosis in patients with bladder cancer. Aging (Albany NY) 2020;12:21582-96. [PMID: 33175697 DOI: 10.18632/aging.103947] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Chen L, Li W, Li Z, Song Y, Zhao J, Chen Z, Kazobinka G, Li L, Xing Y, Hou T. circNUDT21 promotes bladder cancer progression by modulating the miR-16-1-3p/MDM2/p53 axis. Mol Ther Nucleic Acids 2021;26:625-36. [PMID: 34703648 DOI: 10.1016/j.omtn.2021.08.032] [Reference Citation Analysis]
23 Zou Y, Du Y, Cheng C, Deng X, Shi Z, Lu X, Hu H, Qiu J, Jiang W. FAT10 promotes the progression of bladder cancer by upregulating HK2 through the EGFR/AKT pathway. Exp Cell Res 2021;398:112401. [PMID: 33253711 DOI: 10.1016/j.yexcr.2020.112401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
24 Fu J, Wang Y. Identification of a Novel Pyroptosis-Related Gene Signature for Predicting Prognosis in Bladder Cancer. Cancer Invest 2021;:1-17. [PMID: 34644219 DOI: 10.1080/07357907.2021.1991944] [Reference Citation Analysis]
25 Yamada Y, Kato M, Arai T, Sanada H, Uchida A, Misono S, Sakamoto S, Komiya A, Ichikawa T, Seki N. Aberrantly expressed PLOD1 promotes cancer aggressiveness in bladder cancer: a potential prognostic marker and therapeutic target. Mol Oncol 2019;13:1898-912. [PMID: 31199049 DOI: 10.1002/1878-0261.12532] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
26 Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B, van der Heijden MS, Gillessen S; ESMO Guidelines Committee. BLADDER CANCER: ESMO CLINICAL PRACTICE GUIDELINE FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP. Ann Oncol 2021:S0923-7534(21)04827-4. [PMID: 34861372 DOI: 10.1016/j.annonc.2021.11.012] [Reference Citation Analysis]
27 Reitblat C, Bellmunt J, Gershman B. Management of Clinically Regional Node-Positive Urothelial Carcinoma of the Bladder. Curr Oncol Rep 2021;23:24. [PMID: 33559760 DOI: 10.1007/s11912-021-01018-w] [Reference Citation Analysis]
28 Zhou Y, Song X, Li X, Li H, Peng Y. Serum LUCAT1 implicates the pathogenesis of muscle-invasive bladder cancer via targeting miR-199a-5p and miR-199b-5p. J Mol Histol 2020;51:583-91. [PMID: 32844284 DOI: 10.1007/s10735-020-09907-3] [Reference Citation Analysis]
29 Horwich A, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Van Der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, DeBlok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Carmen Mir M, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Vahr Lauridsen S, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Vives Rivera FA, Wiegel T, Wiklund P, Williams A, Zigeuner R, Witjes JA. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. Ann Oncol 2019;30:1697-727. [PMID: 31740927 DOI: 10.1093/annonc/mdz296] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
30 Rebhan K, Gust KM. [Locally advanced or oligometastatic bladder cancer-role of local treatment of the primary tumor and metastases]. Urologe A 2021;60:1555-60. [PMID: 34825935 DOI: 10.1007/s00120-021-01712-4] [Reference Citation Analysis]
31 Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees. Eur Urol 2020;77:223-50. [PMID: 31753752 DOI: 10.1016/j.eururo.2019.09.035] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 12.3] [Reference Citation Analysis]
32 Bochner BH. Postchemotherapy Surgery for Advanced Urothelial Cancer: Another Tool To Improve Outcome. Eur Urol 2018;73:558-9. [PMID: 29289404 DOI: 10.1016/j.eururo.2017.12.015] [Reference Citation Analysis]
33 Martel G, Bertens KA, Canil C. Surgical Management of Genitourinary Cancer Liver Metastases. Surg Oncol Clin N Am 2021;30:89-102. [PMID: 33220811 DOI: 10.1016/j.soc.2020.08.003] [Reference Citation Analysis]
34 Zhou Y, Chu X, Yi Y, Hao Z, Zheng X, Yuxin T, Dai Y. MRS1754 inhibits proliferation and migration of bladder urothelial carcinoma by regulating mitogen-activated protein kinase pathway. J Cell Physiol 2019;234:11360-8. [PMID: 30565699 DOI: 10.1002/jcp.27793] [Reference Citation Analysis]
35 Lievore E, Runza L, Ghidini M, Galassi B, Gallioli A, Bebi C, Boeri L, Blundo C, Rossi CF, Longo F, Albo G, Montanari E, DE Lorenzis E. Micropapillary Bladder Cancer Metastatic to the Breast: A Case Report and Brief Literature Review. In Vivo 2021;35:453-9. [PMID: 33402496 DOI: 10.21873/invivo.12278] [Reference Citation Analysis]
36 Bianchi FM, Romagnoli D, D'Agostino D, Corsi P, Giampaoli M, Salvaggio A, Schiavina R, Brunocilla E, Artibani W, Porreca A. Is robotic approach useful to palliate advanced bladder cancer? A monocentric single surgeon experience. Cent European J Urol 2019;72:113-20. [PMID: 31482017 DOI: 10.5173/ceju.2019.1902] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Luzzago S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Tian Z, Shariat SF, Saad F, Cobelli O, Karakiewicz PI. The effect of radical cystectomy on survival in patients with metastatic urothelial carcinoma of the urinary bladder. J Surg Oncol 2019;120:1266-75. [DOI: 10.1002/jso.25717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
38 Nakagawa T. Lymph node dissection for bladder cancer: Current standards and the latest evidence. Int J Urol 2021;28:7-15. [PMID: 33145855 DOI: 10.1111/iju.14398] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
39 Zhang N, Chen S, Wu L, Wu Y, Jiang G, Shao J, Chen L, Sun J, Na R, Wang X, Xu J. Identification of Cancer-Specific Methylation of Gene Combination for the Diagnosis of Bladder Cancer. J Cancer 2019;10:6761-6. [PMID: 31777606 DOI: 10.7150/jca.28192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
40 Tao L, Pan X, Zhang L, Wang J, Zhang Z, Zhang L, Liang C. Marital Status and Prognostic Nomogram for Bladder Cancer With Distant Metastasis: A SEER-Based Study. Front Oncol 2020;10:586458. [PMID: 33194738 DOI: 10.3389/fonc.2020.586458] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
41 Yan D, Dong W, He Q, Yang M, Huang L, Kong J, Qin H, Lin T, Huang J. Circular RNA circPICALM sponges miR-1265 to inhibit bladder cancer metastasis and influence FAK phosphorylation. EBioMedicine 2019;48:316-31. [PMID: 31648990 DOI: 10.1016/j.ebiom.2019.08.074] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
42 Chen Z, He S, Zhan Y, He A, Fang D, Gong Y, Li X, Zhou L. TGF-β-induced transgelin promotes bladder cancer metastasis by regulating epithelial-mesenchymal transition and invadopodia formation. EBioMedicine 2019;47:208-20. [PMID: 31420300 DOI: 10.1016/j.ebiom.2019.08.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
43 Ilijazi D, Abufaraj M, Hassler MR, Ertl IE, D'Andrea D, Shariat SF. Waiting in the wings: the emerging role of molecular biomarkers in bladder cancer. Expert Rev Mol Diagn 2018;18:347-56. [PMID: 29542328 DOI: 10.1080/14737159.2018.1453808] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
44 Pak S, You D, Jeong IG, Song C, Lee J, Hong B, Hong JH, Kim C, Ahn H. Induction Chemotherapy Followed by Surgery Versus Upfront Radical Cystectomy in Patients With Clinically Node-positive Muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer 2019;17:e420-8. [DOI: 10.1016/j.clgc.2019.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
45 Hou G, Xu W, Jin Y, Wu J, Pan Y, Zhou F. MiRNA-217 accelerates the proliferation and migration of bladder cancer via inhibiting KMT2D. Biochem Biophys Res Commun 2019;519:747-53. [PMID: 31547991 DOI: 10.1016/j.bbrc.2019.09.029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
46 Dursun F, Mackay A, Guzman JCA, Wenker E, Klaassen Z, O'Malley P, Bhindi B, Perez CO, Xu J, Roh T, Sonpavade G, Wallis CJD, Satkunasivam R. Utilization and outcomes of metastasectomy for patients with metastatic urothelial cancer: An analysis of the national cancer database. Urol Oncol 2021:S1078-1439(21)00333-1. [PMID: 34348861 DOI: 10.1016/j.urolonc.2021.07.015] [Reference Citation Analysis]
47 Wu Q, Wong JPC, Kwok HF. Putting the Brakes on Tumorigenesis with Natural Products of Plant Origin: Insights into the Molecular Mechanisms of Actions and Immune Targets for Bladder Cancer Treatment. Cells 2020;9:E1213. [PMID: 32414171 DOI: 10.3390/cells9051213] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
48 Kanzaki R, Suzuki O, Kanou T, Ose N, Funaki S, Shintani Y, Minami M, Tamari K, Otani K, Seo Y, Isohashi F, Ogawa K, Okumura M. The short-term outcomes of pulmonary metastasectomy or stereotactic body radiation therapy for pulmonary metastasis from epithelial tumors. J Cardiothorac Surg 2020;15:43. [PMID: 32103767 DOI: 10.1186/s13019-020-1079-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Han H, Yu F, Wu C, Dai L, Ruan Y, Cao Y, He J. Trends and Utilization of Inpatient Palliative Care Among Patients With Metastatic Bladder Cancer. J Palliat Care 2021;36:105-12. [PMID: 32406315 DOI: 10.1177/0825859720924936] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Cattaneo F, Motterle G, Zattoni F, Morlacco A, Dal Moro F. The Role of Lymph Node Dissection in the Treatment of Bladder Cancer. Front Surg 2018;5:62. [PMID: 30349822 DOI: 10.3389/fsurg.2018.00062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
51 Muilwijk T, Akand M, Van der Aa F, Dumez H, De Meerleer G, Van Raemdonck D, De Leyn P, Van Poppel H, Albersen M, Joniau S. Metastasectomy of oligometastatic urothelial cancer: a single-center experience. Transl Androl Urol 2020;9:1296-305. [PMID: 32676413 DOI: 10.21037/tau-19-624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Hu J, Zheng Z, Zheng J, Xie W, Su H, Yang J, Xu Z, Shen Z, Yu H, Fan X, Kong J, Han J. A Model for Identifying Optimal Patients for Primary Tumor Resection in Patients With Metastatic Bladder Cancer. Front Oncol 2022;11:809664. [DOI: 10.3389/fonc.2021.809664] [Reference Citation Analysis]
53 Kanzaki R, Kanou T, Ose N, Funaki S, Minami M, Tajima T, Fujii M, Ohno Y, Shintani Y. Proposal of a Useful Surrogate Endpoint of the Overall Survival in Patients Undergoing Pulmonary Metastasectomy: The Time to Local Therapy Failure. World J Surg 2019;43:2640-6. [PMID: 31243525 DOI: 10.1007/s00268-019-05071-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Abufaraj M, Kimura S, Haitel A, Iwata T, Isleem U, D'Andrea D, Soria F, Mori K, Rink M, Bensalah K, Rouprêt M, Margulis V, Briganti A, Karakiewicz PI, Shariat SF. The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. Urol Oncol 2020;38:685.e17-25. [PMID: 32381392 DOI: 10.1016/j.urolonc.2020.03.030] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Cao Y, Tian T, Li W, Xu H, Zhan C, Wu X, Wang C, Wu X, Wu W, Zheng S, Xie K. Long non-coding RNA in bladder cancer. Clin Chim Acta 2020;503:113-21. [PMID: 31940466 DOI: 10.1016/j.cca.2020.01.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
56 Zhan Y, Chen Z, Li Y, He A, He S, Gong Y, Li X, Zhou L. Long non-coding RNA DANCR promotes malignant phenotypes of bladder cancer cells by modulating the miR-149/MSI2 axis as a ceRNA. J Exp Clin Cancer Res. 2018;37:273. [PMID: 30419948 DOI: 10.1186/s13046-018-0921-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 54] [Article Influence: 11.3] [Reference Citation Analysis]
57 Hasebe K, Naiki T, Oda R, Etani T, Iida K, Sugiyama Y, Nozaki S, Ando R, Kawai N, Nakanishi R, Yasui T. Long-term survival of a patient with pulmonary metastatic urothelial carcinoma following metastasectomy. Urol Case Rep 2018;21:52-5. [PMID: 30202736 DOI: 10.1016/j.eucr.2018.08.024] [Reference Citation Analysis]
58 Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, Hernández V, Linares Espinós E, Lorch A, Neuzillet Y, Rouanne M, Thalmann GN, Veskimäe E, Ribal MJ, van der Heijden AG. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol 2021;79:82-104. [PMID: 32360052 DOI: 10.1016/j.eururo.2020.03.055] [Cited by in Crossref: 134] [Cited by in F6Publishing: 149] [Article Influence: 67.0] [Reference Citation Analysis]
59 Al-Alao O, Mueller-Leonhard C, Kim SP, Amin A, Tucci C, Kott O, Mega A, Golijanin D, Gershman B. Clinically node-positive (cN+) urothelial carcinoma of the bladder treated with chemotherapy and radical cystectomy: Clinical outcomes and development of a postoperative risk stratification model. Urol Oncol 2020;38:76.e19-28. [PMID: 31590968 DOI: 10.1016/j.urolonc.2019.09.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
60 Oguzhan S, Sponholz S, Schirren M, Mese M, Schirren J. Metastases of Urothelium Carcinoma: Differential Diagnosis, Resection, and Survival. Thorac Cardiovasc Surg 2021. [PMID: 33862636 DOI: 10.1055/s-0041-1727150] [Reference Citation Analysis]
61 Wang W, Chen S, Song X, Gui J, Li Y, Li M. ELK1/lncRNA-SNHG7/miR-2682-5p feedback loop enhances bladder cancer cell growth. Life Sci 2020;262:118386. [PMID: 32898531 DOI: 10.1016/j.lfs.2020.118386] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
62 Li Y, Zhong W, Zhu M, Hu S, Su X. Nodal regulates bladder cancer cell migration and invasion via the ALK/Smad signaling pathway. Onco Targets Ther 2018;11:6589-97. [PMID: 30323631 DOI: 10.2147/OTT.S177514] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
63 Moschini M, Xylinas E, Zamboni S, Mattei A, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A; RISC Investigators. Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. Eur Urol Oncol 2020;3:94-101. [PMID: 31307962 DOI: 10.1016/j.euo.2019.06.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
64 Liao W, Ye T, Liu H. Prognostic Value of Inducible Nitric Oxide Synthase (iNOS) in Human Cancer: A Systematic Review and Meta-Analysis. Biomed Res Int 2019;2019:6304851. [PMID: 31275981 DOI: 10.1155/2019/6304851] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
65 Makrakis D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Di Lorenzo G, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. BJU Int 2021. [PMID: 34597472 DOI: 10.1111/bju.15603] [Reference Citation Analysis]
66 Mazzone E, Preisser F, Nazzani S, Tian Z, Fossati N, Gandaglia G, Gallina A, Soulieres D, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder. Clin Genitourin Cancer 2019;17:105-113.e2. [PMID: 30527745 DOI: 10.1016/j.clgc.2018.11.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]